Novartis reported that remibrutinib, its BTK inhibitor marketed as Rhapsido for chronic spontaneous urticaria, achieved “superiority” over Aubagio in two Phase 3 trials in relapsing multiple sclerosis. The company said the drug reduced annualized relapse rates and inflammatory brain lesions, with disability progression effects described as clinically meaningful. Novartis emphasized liver safety comparability versus an established comparator used in prior BTK development programs. The company plans to share the trial results with regulators, and investors will focus on the detailed safety and efficacy profile given the class’s history of liver-related side effects in autoimmune studies.